Introduction
============

The use of highly active antiretroviral therapy (HAART) has dramatically improved the quality of life and overall survival of adults and children infected with HIV-1. However, suboptimal exposure to HAART (e.g. due to poor adherence, inadequate dose) can rapidly select for drug resistance mutations, and ultimately lead to virological failure. Given the dynamics of HIV viral evolution, almost complete (\> 95%) adherence to combination therapy is required to maximally suppress viral load and avoid selection of resistant strains \[[@B1]\].

Moreover, children and adolescents seem to be more prone to selection of drug resistant variants for both biological and behavioral reasons. Plasma viral loads are much higher in children compared to adults. Therefore, children require more potent HAART to achieve virological suppression \[[@B1]\]. Loss of adherence, long lasting exposure to drugs and multi-drug resistance can determine a more difficult scenario to manage a therapeutical failure than in adults.

Case report
===========

We describe a 15-year-old Caucasian male, with vertically acquired HIV-1 infection, who failed several lines of antiretroviral therapies.

He was born premature, at 22^nd^week of gestation, with a spontaneous delivery, to a mother who did not assume any therapy during pregnancy. His father died few months after his birth. He remained off medications until he was 1-year-old. He was started monotherapy with zidovudine in 1993, didanosine in 1994, restarted zidovudine in 1995, and then was treated with stavudine in 1996. All antiretroviral therapies were done without compliance by the mother-side and were discontinued by her after some months. In 1997, the patient started the first protease inhibitor (PI) based HAART with ritonavir plus zidovudine plus lamivudine, without immuno-virological response. The same happened with all the others regimens (Table [1](#T1){ref-type="table"}). In the end, he had failed four ritonavir-boosted PIbased and one nevirapine-based HAART. The patient\'s viral load had never been suppressed from his birth, his CD4 cells count nadir was 67 cells/μl (5.4%) and his viral load zenith was 89,700 copies/mL.

###### 

Summary of HAART regimens and genotypic resistance tests of the patient

  Antiretroviral Therapy                                                                                                Start      End        VL      CD4+   CD4+(%)   Reason of change
  --------------------------------------------------------------------------------------------------------------------- ---------- ---------- ------- ------ --------- ---------------------
  Zidovudine                                                                                                            15/11/93   09/12/93   N.A.    1196   23,2      no compliance
                                                                                                                                                                       
  Didanosine                                                                                                            10/12/93   28/04/94   N.A.    1328   24,2      no compliance
                                                                                                                                                                       
  Zidovudine                                                                                                            01/07/95   07/06/96   N.A.    316    13,2      no compliance
                                                                                                                                                                       
  Stavudine                                                                                                             28/06/96   27/02/97   1000    67     5,4       no compliance
                                                                                                                                                                       
  Zidovudine + lamivudine                                                                                               28/02/97   02/09/97   27000   103    8,2       virological failure
                                                                                                                                                                       
  Zidovudine + lamivudine +ritonavir                                                                                    03/09/97   20/03/98   2200    251    14,2      virological failure
                                                                                                                                                                       
  Didanosine + nelfinavir +saquinavir                                                                                   12/10/98   15/07/01   248     129    5,6       virological failure
                                                                                                                                                                       
  Stavudine + didanosine + lopinavir/r                                                                                  24/07/01   23/06/04   45000   259    14        virological failure
                                                                                                                                                                       
  Didanosine + tenofovir + lopinavir/r                                                                                  24/06/04   09/03/05   2800    644    22        virological failure
                                                                                                                                                                       
  Didanosine + tenofovir + nevirapine                                                                                   10/03/05   10/11/05   7700    465    20        virological failure
                                                                                                                                                                       
  GRT: RTRM: D67N, K70R, V106A, Y181C, T215F, K219Q, F227L; PIRM: L10I, L24I, L33F, M36I/L, I54V, L63P, V82A                                                           
                                                                                                                                                                       
  Abacavir + lamivudine + Fos-Amprenavir/r                                                                              11/11/05   11/04/07   19600   334    17        no compliance
                                                                                                                                                                       
  GRT: RTRM: D67N, K70R, Y181C, M184V, T215F, K219Q; PIRM: L10I, L24I, L33F, M36L, F53L I54V, L63P, G73S, V82A                                                         
                                                                                                                                                                       
  Abacavir + lamivudine + lopinavir/r                                                                                   12/04/07   12/02/08   14800   410    17        virological failure
                                                                                                                                                                       
  GRT: RTRM: D67N, K70R, Y181C, M184V, T215F, K219Q; PIRM: L10I, I13V, L24I, L33F, M36L, F53L, I54V, L63P, G73S, V82A                                                  
                                                                                                                                                                       
  Abacavir + lamivudine + darunavir/r + etravirine                                                                      13/02/08   ongoing    89700   287    16        ongoing

r: ritonavir; GRT: genotypic resistance test; RTRM: reverse transcriptase mutations; PIRM: protease mutations

Plasma HIV-1 RNA was measured at baseline and during therapy using a commercial assay, the Versant HIV-1 RNA 3.0 Assay (bDNA; Siemens Medical Solutions Diagnostics, Malvern, PA), with a dynamic range of 50-500,000 HIV-1 RNA copies/mL. CD4 cells count was determined by direct immunofluorescence in flow cytometry (Beckman Coulter, Fullerton, CA). Genetic analysis of the pol gene including both HIV-1 reverse transcriptase (codons 4-99) and protease (codons 35-247) regions was performed using the Trugene HIV-1 Genotyping Kit (Siemens Medical Solutions Diagnostic).

In January 2008, his clinical conditions were good, CDC status B2 (bacterial pneumonia), and height 167 cm, weight 54 kg, and body mass index (BMI) 19.36. His viral load was 89,700 copies/mL and the CD4 cells count was 287 cells/μl (16%). The genotype revealed the presence of D67N, K70R, Y181C, M184V, T215F, K219Q mutations within transcriptase and L10I, I13V, L24I, L33F, E34Q, M36L, F53L, I54V, L63P, G73S, V82A, N83D mutations within protease genes (Table [1](#T1){ref-type="table"}). In summary, there were multiple drug resistance (MDR) mutations, which conferred high-level resistance to most currently available antiretroviral agents, included class-resistance to the non-nucleoside reverse transcriptase inhibitors (NNRTIs).

In that period there was also a change in his family situation: the mother, who had been in jail for 6 months, was released and began to be compliant to her therapy. Therefore, after deep counseling to him and the mother, we decided to prescribe a new HAART. Darunavir/ritonavir and etravirine were provided for compassionate use by Tibotec (Cork, Ireland) and their use was approved by San Martino Hospital Ethical Committee (Genoa, Italy). The patient started these new drugs together with fixed dose abacavir/lamivudine combination. Based on the weight, he could take the adult dose of each drug.

After one month of therapy, viral load became undetectable for the first time in the patient\'s life. During the first year of follow-up, viral load remained stably undetectable, meanwhile CD4 cells count and percentage increased to 706 cells/mL and 18%, respectively. Laboratory data remained within normal range showing no hepatic and metabolic toxicity. In particular, median aspartate aminotransferase (AST, normal range, r, 0-40) was 33 U/L, alanine aminotransferase (ALT, r 0-40) 23 U/L, γ glutamyltranspeptidase (GGT, r 11-50) 28 U/L, plasma glucose (r 65-110) 83 mg/dL, glycated haemoglobin (r 4.3-5.8) 5.1%, insulin levels (r 2.0-25) 5.8 mU/L, triglycerides (r 4-170) 110 mg/dL, total cholesterol (r 130-200) 177 mg/dL, HDL-cholesterol 31.5 mg/dL, and LDL-cholesterol 118 mg/dL.

The new regimen was well tolerated and adherence to treatment was reported excellent throughout the entire period, monitored by performing monthly outpatient\'s visit and calling the patient every two weeks.

Discussion
==========

Strategies for the management of HIV-infected patients with extensive previous treatment and drug resistance are very limited, especially in children and adolescents. As a matter of fact, in this population the use of experimental agents, with a close follow-up, must be considered. Besides, a careful monitoring of adherence is needed for a successful therapy.

This case report has examined the successful inhibition of viral replication in a MDR patient who exhibited very poor compliance with previous therapies. The treatment regimen consisted of a new and recently approved combination used in adults, based on darunavir/ritonavir and etravirine, in addition to a well-known nucleoside reverse transcriptase inhibitor backbone \[[@B2]\]. In the first year of therapy the CD4 cells count increased and viral load fell to undetectable levels. Tolerability was good and no serious adverse events were recorded. The patient is still following this regimen.

This antiretroviral regimen has been chosen in consequence of the poor compliance of the patient showed during the past years. Fixed dose abacavir/lamivudine combination was used as backbone. Abacavir seemed to maintain a partial activity, at least according to some interpretation alghorithms, and was preferred to tenofovir which would have been a safer choice based on mutational pattern, by reason of previously tested poor tolerability (proteinuria). Lamivudine was maintained in order to affect viral fitness.

Darunavir, in combination with low-dose ritonavir, approved in adult since July 2007 in Italy, has shown potent antiviral activity and good tolerability in threeclass-experienced HIV-infected patients with limited or no treatment options \[[@B3]\]. Recent reports have highlighted that 11 mutations of which 5 major (I50V, I54L/M, L76V and I84V) and 6 minor (V11I, V32I, L33F, I47V, G73S and L89V), selected in patients failing it, are associated with decreased susceptibility to darunavir \[[@B4]\].

In our patient the presence of three minor mutations (L33F, G73S and L89V) had not compromised the efficacy of the drug. This fact, probably, confirms the importance of number, type, pattern of association and weight of mutations.

Etravirine, currently available in Italy only in the expanded access program (TMC125-c214), is a second generation NNRTI that appears to be effective against a variety of HIV viruses that are resistant to efavirenz and nevirapine. Three or more mutations are associated with decreased virologic response \[[@B5]\]. In our patient there was only one mutation (Y181C), but with a weight factor of 2.5, using the weighted genotypic score. This score has been provided by Vingerhoets J et al. analyzing the database of the patients enrolled in the DUET-1 and DUET-2 trials \[[@B6]\]. The sum of the different weighted factors predicts virological response to etravirine, and in our patient this should have been an intermediate response.

One of the first studies, assessing the role of etravirine and darunavir in HIV-1-infected subjects with no treatment options, showed highly effective virological and immunological responses over 24 weeks of therapy with no new safety concerns or unexpected pharmacokinetic interactions \[[@B7]\].

Enfuvirtide could be another good choice, also because it is approved for pediatric use, but its way of administration, with often-intolerable subcutaneous injection site reactions, would have never been accepted from the patient. The genotypic test showed also a susceptibility to tipranavir (one major I54V and one accessory mutation L33F), confirmed from the tipranavir-mutation-score (Score = 1) that could allow us to choose that drug in the new regimen \[[@B8]\]. We decided, however, to choose darunavir, because etravirine should not be administered with tipranavir \[[@B9]\].

In conclusion, this case report underlines the importance of the continuous development of new drugs and the great need of their approval also for pediatric/adolescent use, as clinicians will continue to encounter an increasing number of MDR HIV-infected youths, who have extensive experience with previous treatments. It is, indeed, of extreme importance to evaluate the compliance with all the available methods (e.g. self reporting calendars, records of missed doses, pill counts, interview questionnaires, therapeutic drug monitoring), knowing that the most common cause of treatment failure is insufficient adherence, which can be found in 25-30% of children \[[@B10]\].

In particular, adolescents with vertically acquired-HIV-infection may require complicated regimens, because of significant antiretroviral treatment experience and poor adherence.

So it is clear the importance of having parents and/or caregivers who can do an accurate and consistent monitoring and improve the children/adolescent\'s compliance.
